جستجوی استاد راهنمای دانشگاهی

برای مسیر پژوهشی‌تان، استاد راهنما، استاد دانشگاه و پژوهشگر مناسب را پیدا کنید و با آن‌ها ارتباط بگیرید.

نمایش ۷۲۱-۷۳۵ از ۱۰٬۴۰۱ استاد راهنما

اطلاعات پروفایل‌ها از صفحات عمومی دانشگاه‌ها گرفته شده و ممکن است به‌روز نباشد.

Pedro Machadoمشاهده پروفایل

استاد

University College LondonUnited Kingdom

Pedro Machado FRCP PhD serves as Professor of Rheumatology and Neuromuscular Diseases at University College London (UCL), holding dual appointments in the Department of Neuromuscular Diseases (Institute of Neurology) and the Centre for Rheumatology (Division of Medicine). His clinical work spans University College London Hospitals (UCLH) and Northwick Park Hospital, where he leads specialist spondyloarthritis and myopathy/myositis clinics alongside the UCLH needle muscle biopsy service implemented in 2023. His research program focuses on new therapeutic strategies and outcome prediction in rheumatic diseases, with particular emphasis on muscle diseases and axial spondyloarthritis. Recent expansion includes investigation of COVID-19 outcomes in patients with rheumatic and neuromuscular conditions. His work integrates epidemiological approaches with clinical trial design across multiple international collaborations. Analysis of his 15 most recent publications reveals strong concentration in axial spondyloarthritis diagnostics (7 articles), COVID-19 rheumatology implications (5 articles), and myositis therapeutics (2 articles), demonstrating consistent leadership in developing classification criteria, imaging protocols, and pandemic response guidelines through major international consortia including EULAR, ASAS, and the COVID-19 Global Rheumatology Alliance. Michael Mason Award (British Society for Rheumatology, 2023) for clinical and scientific research excellence EULAR Honorary Member Award (2024) for outstanding service 15 total scientific prizes including four major fellowships Recipient of over £8 million research funding Professor Machado actively mentors through multiple educational channels including the EULAR Annual Epidemiology Course and UCL's Neuromuscular Disease Programme. His leadership extends to the needle muscle biopsy service he established at UCLH in 2023, alongside significant contributions to international clinical guidelines through his roles on the ASAS Executive Committee and EULAR steering groups. He directs research activities through the UCL Department of Neuromuscular Diseases and Centre for Rheumatology, collaborating with the Muscle Study Group, British Myology Society, and international networks including MIHRA where he serves as Vice-Chair.

پروفایل رسمی دانشگاه

Wolfgang Zachariaeمشاهده پروفایل

استاد

Max Planck Institute of BiochemistryGermany

Dr. Wolfgang Zachariae is a Group Leader at the Max Planck Institute of Biochemistry in Martinsried, Germany, where he heads the "Chromosome Biology" research group. His laboratory focuses on understanding the molecular mechanisms of meiosis, particularly chromosome segregation and the role of cohesin in this process. Dr. Zachariae's educational background includes: PhD (summa cum laude) from Heinrich-Heine University, Düsseldorf, Germany (1990-1994), with Prof. Karin Breunig on "Regulation of the transcriptional activator Lac9" Diploma Thesis with Prof. Karin Breunig on "Enrichment of the transcription factor Lac9 from the yeast Kluyveromyces lactis" (1988-1990) Studies in Biology at Heinrich-Heine University, Düsseldorf, Germany (1984-1988) Postdoctoral Fellowship at the Institute of Molecular Pathology (IMP), Vienna, Austria (1994-1999), in the Laboratory of Prof. Kim Nasmyth, focusing on "cell cycle control by the anaphase-promoting complex in budding yeast" Dr. Zachariae's research focuses on the molecular biology of chromosome segregation during meiosis. His group uses baker's yeast as a model organism to study how chromosomes are correctly separated during the two meiotic divisions. A key focus is on cohesin, a molecular "glue" that holds chromosome pairs together, and how its regulated destruction ensures proper chromosome separation. His research employs diverse methodologies including genetics, biochemistry, video microscopy, and computational simulations of biochemical reactions. This work has significant medical relevance as errors in meiotic chromosome segregation are leading causes of infertility, miscarriage, and chromosome abnormalities like Down syndrome. Analysis of Dr. Zachariae's recent publications reveals a consistent focus on the molecular mechanisms of meiosis, particularly the regulation of cohesin and the anaphase-promoting complex (APC/C). His work spans from fundamental molecular mechanisms (such as phosphorylation of Rec8 by casein kinase) to the broader implications for gamete formation and chromosome segregation. The research demonstrates an interdisciplinary approach combining yeast genetics with advanced biochemical and imaging techniques. Dr. Zachariae has made significant contributions to the field of chromosome biology through his publications in top-tier journals including Cell, EMBO Journal, Developmental Cell, and Current Biology. His work on the regulation of meiotic chromosome segregation has provided fundamental insights into cell division processes that are conserved across eukaryotes. Dr. Zachariae leads an active research group consisting of PhD students (Nikoleta Milanovic, Addison E. Noronha, Vinal Massaad, Magdalena Matijevic), postdoctoral researchers (Olha Biriuk, Oleksii Lyzak, Marc Llavanera, Tugce Öz-Yoldas), and technical staff. His laboratory investigates the molecular mechanisms of chromosome segregation during meiosis using baker's yeast as a model system. The group has developed sophisticated approaches combining genetics, biochemistry, live-cell imaging, and computational modeling to understand how cohesin is regulated during the two meiotic divisions.

پروفایل رسمی دانشگاه

Ning Chengمشاهده پروفایل

استادیار

University of CalgaryCanada

Ning Cheng is an Assistant Professor (Teaching & Research) at the University of Calgary's Faculty of Veterinary Medicine, with affiliations to the Alberta Children's Hospital Research Institute (ACHRI) and Hotchkiss Brain Institute (HBI). Their research focuses on neurodevelopmental disorders, particularly autism and Fragile X Syndrome, using rodent models to investigate mechanisms and develop experimental therapeutics. PhD in neuroscience from Johns Hopkins School of Medicine Postdoctoral work on neurological disorders at NIH Research spans molecular mechanisms, neural circuitry, and translational approaches to address social, communication, and behavioral challenges in autism spectrum disorders. The lab utilizes in vivo recording/modulation of brain activity, biochemical analyses, and multidisciplinary collaborations. Recent publications highlight expertise in EEG biomarker discovery, auditory processing abnormalities, ketogenic diet interventions, and ERK pathway modulation in mouse models of neurodevelopmental conditions. Key technologies developed include wireless cortical hemodynamic monitoring systems (TinyIOMS) and open-source electrophysiology tools (OSERR). As part of ACHRI's Precision Medicine & Disease Mechanisms program and HBI's Neurodevelopment/SCNIP strategic initiatives, Cheng contributes to university-wide efforts in Brain and Mental Health (2015-2021) and Child Health and Wellness (2020-2025).

پروفایل رسمی دانشگاه

Cianflone Domenicoمشاهده پروفایل

دانشیار

Vita-Salute San Raffaele UniversityItaly

Cianflone Domenico is an Associate Professor of Cardiovascular Diseases at Vita-Salute San Raffaele University in Milan, Italy. He serves as Director of the Cardiac Rehabilitation Unit at San Raffaele Hospital and has held various clinical and academic positions throughout his distinguished career in cardiology. His educational background includes: Medical Degree with Honors, University of Milan (1980) Specialization in Cardiology, University of Milan (1982) Research Fellow, Cardiology Division, Royal Post-Graduate Medical School, Hammersmith Hospital, London (1983-1986) Honorary Fellowship, Duke University Medical Center, USA (1986) Professor Cianflone's research focuses on the causal mechanisms and precipitating factors of myocardial infarction and other coronary syndromes, innovative patient stratification models, and the development of Health IT/telemedicine solutions for cardiovascular care. His work bridges clinical cardiology with digital health technologies to improve cardiovascular disease prevention and management, with particular emphasis on cardiac rehabilitation, coronary artery disease mechanisms, and cardiovascular applications of health information systems. His recent publications demonstrate a strong emphasis on cardiac rehabilitation, postoperative cardiac complications, and the application of emerging technologies in cardiology. There's a clear trend toward exploring the intersection of traditional cardiology with digital health solutions, rehabilitation protocols, and personalized approaches to cardiovascular disease management, with numerous publications in high-impact journals like the International Journal of Cardiology. Professor Cianflone has held significant editorial positions including: Deputy Editor-in-Chief, International Journal of Cardiology (2016-present) Deputy Editor, International Journal of Cardiology: Hypertension (2018-present) Editorial Board, Italian Heart Journal (1998-2000) Editor-in-Chief, Medscape Italia Cardiologia (1999-2001) Professor Cianflone has supervised 24 degree theses and 12 specialization theses at UniSR, with four of these theses leading to Young Researcher awards and international recognitions from organizations like SISA, GICR, and the American College of Cardiology. He has coordinated or participated in 15 research projects funded by the European Commission, European Social Fund, European Space Agency, Ministry of Health, and Ministry of University and Scientific Research. Additionally, he has served as principal investigator in 15 international clinical trials related to cardiovascular disease and held numerous positions in international commissions at the European Society of Cardiology, American College of Cardiology, International Heart Health Society, and NIH. As Director of the Cardiac Rehabilitation Unit at San Raffaele Hospital, Professor Cianflone leads a multidisciplinary team focused on high-intensity rehabilitative care for patients following advanced cardiac surgery, structural heart procedures, and complex coronary syndromes. His unit provides comprehensive cardiovascular prevention and rehabilitation services with a focus on reducing global cardiovascular risk, including hypertension, dyslipidemia, and diabetes management.

پروفایل رسمی دانشگاه

Julian Hurdleمشاهده پروفایل

استاد

Texas A&M UniversityUnited States

Julian Hurdle, PhD, is a Professor at Texas A&M University and Director of the Center for Infectious and Inflammatory Diseases (CIID). His research focuses on antibiotic resistance in Clostridium difficile , novel therapeutic strategies, and chemical genetic approaches to pathogenic mechanisms. Research Interests: His multi-disciplinary work bridges high-throughput screening of chemical libraries, target identification via genomics, and in vivo modeling to understand C. difficile resistance and develop therapies. Collaborations with medicinal chemists and clinical scientists drive translational goals. Publications: His 15 most recent articles highlight studies on C. difficile's evolution of resistance, membrane-active antibiotics, and antivirulence strategies. Keywords span Microbiology, Pharmacology, and Chemical Genetics, with sub-fields like toxin-inhibiting mechanisms, phytochemicals, and drug hybridization. Academic Contributions: As Director of the IBT Postdoctoral Program, he mentors researchers in infectious disease innovation. His lab integrates molecular biology, animal models, and clinical data to impact human health.

پروفایل رسمی دانشگاه

Saima Hassanمشاهده پروفایل

استادیار

University of MontrealCanada

Saima Hassan, MD, Ph.D., FRCSC, serves as an Assistant Professor in the Department of Surgery at the Faculty of Medicine, University of Montreal, and practices as a Surgical Oncologist at Hôtel-Dieu Hospital within the Centre hospitalier de l'Université de Montréal (CHUM). As a Regular Researcher, she integrates clinical oncology with translational science to advance breast cancer treatment. Educational background: Doctor of Medicine (MD) Doctor of Philosophy (Ph.D.) Her research centers on triple-negative breast cancer and metastasis, with emphasis on translational methodologies including prognostic/predictive biomarker discovery, cellular imaging, and PARP inhibitor therapeutics. This work aims to refine treatment response prediction and develop targeted interventions for aggressive breast cancer subtypes through laboratory-clinical integration. Scientific recognition: Fellow of the Royal College of Surgeons of Canada (FRCSC) No current advisees or specific grant funding details are disclosed in available materials, though her CHUM-affiliated research program focuses on biomarker-driven therapeutic strategies for breast cancer patients.

پروفایل رسمی دانشگاه

Mary Beth Scholandمشاهده پروفایل

دانشیار

University of UtahUnited States

Mary Beth Scholand, MD is an Associate Professor in the Department of Internal Medicine at the University of Utah School of Medicine, specializing in Pulmonary Medicine. She serves as Director of the Interstitial Lung Disease Clinic at University of Utah Hospital and provides clinical care across multiple University of Utah Health locations including Farmington, South Jordan, Sugar House, and University Hospital. Her educational background includes: B.S. from Northwestern University M.D. from Washington University Internal Medicine Internship and Residency at Barnes Hospital Pulmonary Medicine Fellowship at University of Utah School of Medicine Dr. Scholand's research centers on interstitial lung diseases, with primary focus on idiopathic pulmonary fibrosis (IPF), sarcoidosis, and autoimmune lung diseases. She investigates genetic and phenotypic factors in chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILD), while leading clinical trials targeting IPF cures and novel monitoring programs. Her work bridges pulmonary medicine, rheumatology, and oncology through translational research. Analysis of her 15 most recent publications reveals dominant themes in ILD therapeutics, clinical guideline development, and international registry studies. Key trends include antifibrotic drug trials (bexotegrast, pirfenidone), multidisciplinary management frameworks for autoimmune-related ILD, and pandemic-era adaptations in sarcoidosis care. Her research consistently addresses diagnostic challenges, therapeutic innovations, and patient-centered outcomes across pulmonary subspecialties. As Director of the Interstitial Lung Disease Clinic, Dr. Scholand leads a multidisciplinary team managing complex cases through integrated diagnostics and personalized treatment plans. Her clinical trials portfolio demonstrates active grant funding for therapeutic innovations in IPF and ILD, while her guideline contributions to ACR/CHEST and ATS reflect leadership in standardizing global care practices. Patient testimonials consistently highlight her expertise, thoroughness, and compassionate bedside manner, with a 4.9/5 rating from over 457 reviews.

پروفایل رسمی دانشگاه

Yi-Ju Liمشاهده پروفایل

استاد

Duke UniversityUnited States

Yi-Ju Li is Professor of Biostatistics & Bioinformatics at Duke University, where she is also a Member of the Duke Molecular Physiology Institute and part of the Division of Integrative Genomics. Her academic journey at Duke includes progression from Assistant Professor to Associate Professor and now to her current position as full Professor since 2021. Professor Li's research focuses on statistical genetics, particularly the development of statistical methods for understanding the genetic predisposition of human complex diseases. Her work encompasses family-based association methods for quantitative traits, detection of X-linked genes for disease risk, analysis of next generation sequencing data for rare variants, and applications in Alzheimer's disease, Fuchs endothelial corneal dystrophy, and peri-operative genomic studies. She has made significant contributions to understanding the genetic basis of age-at-onset of Alzheimer disease and genetic risk factors for postoperative outcomes in patients undergoing cardiac surgery. Her recent publications reveal a strong trend toward translational research with clinical applications, particularly in drug-induced liver injury, cardiovascular outcomes after surgery, and genetic risk factors for various conditions. Her work bridges statistical methodology development with practical applications in multiple disease areas, demonstrating versatility across hepatic, neurological, cardiovascular, and ophthalmological domains. Professor Li serves as Co-Investigator on multiple significant research grants, including the Drug Induced Liver Injury Network Data Coordinating Center (NIH, 2003-2028), Proteomic Biomarkers Predicting Osteoarthritis Onset and Progression (DoD, 2025-2027), and Neurocognition & Greater Maintenance of Sinus Rhythm in AF (NIA, 2021-2026). Her grant portfolio spans multiple funding agencies including NIH, Department of Defense, and various institutes within NIH. She is actively involved in the Duke Center for Statistical Genetics and Genomics, collaborating with researchers across multiple disciplines to advance genomic research methodologies and applications. Her work demonstrates strong interdisciplinary collaboration between biostatistics, medicine, and clinical research teams at Duke University.

پروفایل رسمی دانشگاه

Fran Aweekaمشاهده پروفایل

استاد

University of California, San FranciscoUnited States

Fran Aweeka is a Professor and Vice Chair of Research at the Department of Clinical Pharmacy, University of California San Francisco (UCSF) School of Pharmacy . She directs the Drug Research Unit (DRU) and serves as the Pharmacology Core Lead for the UCSF Center for AIDS Research . Her research focuses on pharmacokinetic and pharmacodynamic studies of HIV, malaria, and tuberculosis drugs, particularly in vulnerable populations in Africa and the U.S. She actively contributes to the PharmD degree program as a co-director of the Inquiry component and mentors students in pharmacology and international research. As a clinical pharmacologist with over 25 years of experience, Dr. Aweeka investigates drug interactions in co-infected patients, pharmacokinetics in pregnancy and pediatric populations, and mechanisms of HIV-associated inflammation. Her work includes PI roles on NIH R01 grants and leadership in global health initiatives like seasonal malaria chemoprevention studies in Uganda. The DRU under her direction provides advanced analytical techniques for drug quantification in plasma and target tissues, supporting over 30 NIH studies. Her recent research trends include pharmacokinetic-pharmacodynamic modeling of antimalarial and antiretroviral combinations, microvolume plasma assays , and drug exposure-response relationships in resource-limited settings. Publications from 2021–2025 reflect these areas, with emphasis on pregnancy pharmacokinetics , pediatric dosing , and global health pharmacology . Dr. Aweeka holds a PharmD from UCSF (1985) and a BS in Biological Sciences from USC (1981). She is a licensed pharmacist in California and has completed leadership programs like the Mentor Development Program . Her lab supports collaborative projects across national and international institutions, focusing on drug quantification in plasma, dried blood spots, and target cells.

پروفایل رسمی دانشگاه

Sherry Wuمشاهده پروفایل

مدرس ارشد

University of QueenslandAustralia

Dr Sherry Wu is a Senior Lecturer at the University of Queensland , Faculty of Health, Medicine and Behavioural Sciences, within the School of Biomedical Sciences . She leads the Cancer Therapeutics Lab and is affiliated with the Centre for Extracellular Vesicle Nanomedicine . Her research focuses on developing novel cancer therapies, particularly for ovarian and breast cancers, using nanotechnology, RNA therapeutics, and immune modulation. Education: Bachelor of Pharmacy (Honours), The University of Queensland Doctor of Philosophy (PhD), The University of Queensland Graduate Certificate in Translational Cancer Research, University of Texas M.D. Anderson Cancer Center (TRIUMPH program) Research Interests: Dr Wu’s research spans cancer therapeutics , nanomedicine , RNA interference , extracellular vesicles , and immune-oncology . Her lab is dedicated to understanding and overcoming immune suppression in ovarian and breast cancers, developing nanoparticle-based drug delivery systems, and engineering exosomes for therapeutic purposes. Publications & Trends: She has authored over 65 peer-reviewed publications, including high-impact journals such as Nature Communications , Biomaterials , Cancer Immunology, Immunotherapy , and Molecular Therapy . Her work consistently explores innovative delivery systems, miRNA-based therapies, and immune modulation strategies in cancer. Awards & Grants: Cancer Institute NSW Career Development Fellowship NHMRC IDEAS Grants (2023–2026, 2025–2029) Ovarian Cancer Research Foundation Grants Liz Tilberis Early Career Award (2016–2019) NIH R35 Maximizing Investigators’ Research Award Supervision & Mentorship: Dr Wu is actively supervising PhD students in areas such as immune suppression in cancer, nanosystem development, and exosome targeting strategies. She has successfully graduated students and continues to mentor early-career researchers. Labs & Teams: She heads the Cancer Therapeutics Lab at UQ and collaborates with national and international research teams, including the Centre for Extracellular Vesicle Nanomedicine and the Faculty of Health, Medicine and Behavioural Sciences .

پروفایل رسمی دانشگاه

Philip A. Kithasمشاهده پروفایل

استاد بالینی

University of UtahUnited States

Philip A. Kithas, MD, PhD, serves as Clinical Professor of Internal Medicine and Adjunct Associate Professor of Family & Preventive Medicine at the University of Utah School of Medicine, where he directs geriatric care at the Madsen Health Center in Salt Lake City. With 25 years of prior service at the George E. Wahlen Salt Lake Veterans Health Care System—including leadership as General Medicine Section Chief from 1999 to 2006—he transitioned to his current academic-clinical role after retiring from the VA system. His educational background includes: BA in Biology from the University of Utah BS in Human Biology from the University of South Alabama PhD in Pharmacology from the University of South Alabama College MD from the University of South Alabama Residency and Chief Medical Residency at the University of Utah School of Medicine Dr. Kithas' research centers on geriatric cardiovascular medicine, with deep expertise in hypertension management, hyperlipidemia, and anticoagulation protocols for elderly patients. His work addresses the complex interplay of multiple chronic conditions in aging populations, emphasizing patient education and partnership in care. Early career research investigated molecular mechanisms of cardiac function, particularly phosphodiesterase enzyme systems, while recent publications focus on practical clinical approaches for geriatric hypertension. His publication record reveals a clear evolution from foundational molecular cardiology studies in the 1980s-1990s to applied geriatric cardiovascular research in the 2000s-2020s. The 2010-2020 period features significant contributions to hypertension management guidelines for older adults, including considerations for chronic kidney disease and vascular stiffness, while earlier work established critical insights into cardiac enzyme regulation during development. Dr. Kithas has received exceptional patient feedback (5.0/5 from 19 reviews), with testimonials highlighting his compassionate care, thorough explanations, and unprecedented personal follow-up—including evening phone calls to ensure patient compliance. His administrative contributions include quality improvement initiatives across VA clinics and community-based outpatient facilities. As an educator, he has trained generations of medical providers in geriatric care principles, though specific mentee names are not documented. His current work continues to bridge clinical practice, education, and research at the University of Utah's Madsen Geriatric Clinic, with ongoing focus on optimizing cardiovascular outcomes for aging patients.

پروفایل رسمی دانشگاه

Lorenzo Farinaمشاهده پروفایل

استاد

Sapienza University of RomeItaly

Lorenzo Farina is a Full Professor at Sapienza University of Rome's Faculty of Information Engineering, Computer Science and Statistics, specializing in Electronic and Computer Bioengineering (ING-INF/06). With over 25 years of academic leadership, he co-founded Italy's first Bioinformatics degree program and established key oncology precision medicine initiatives, maintaining active collaborations with Harvard Medical School's network medicine division. His educational background includes a cum laude Electronic Engineering degree and PhD in Systems Engineering, both from Sapienza University. These foundational studies evolved into pioneering work in positive linear systems theory, evidenced by his highly-cited Wiley textbook Positive Linear Systems: Theory and Applications (2000). Farina's research centers on network medicine – applying complex network science to molecular medicine since his 2004 breakthrough. His work spans cancer mechanisms (breast, glioblastoma, lung), drug repositioning (including COVID-19 applications), and liquid biopsy biomarker development. Current projects focus on miRNA-based network biomarkers for cancer diagnostics and immunotherapy response prediction, integrating multi-omics data through advanced computational frameworks. Analysis of his 15 most recent publications (2024-2025) reveals dominant themes: sexual dimorphism in cancer networks (MIRROR platform), immunotherapy response signatures, and critical examinations of AI's role in precision medicine. His work consistently bridges computational innovation with clinical applications, particularly in oncology diagnostics and therapeutic optimization. His scientific recognition includes: 2001 Guillemin-Cauer Award for best IEEE Transactions on Circuits and Systems article 2014 SysBio Award for annual best publication Farina actively mentors through interdisciplinary programs he established, including the Network Oncology doctoral program. His laboratory collaborations span Sapienza's Oncogenomics and Immunology Laboratories, Harvard's Channing Division of Network Medicine, and clinical departments in oncology and radiology, driving translational research from computational models to patient applications. He leads multiple research teams focused on network-based diagnostics, including the MIRROR platform for cancer disparity analysis and liquid biopsy development teams investigating circulating miRNA networks for early cancer detection across multiple malignancies.

پروفایل رسمی دانشگاه

C. Michael Gibsonمشاهده پروفایل

استاد پژوهش

Harvard UniversityUnited States

C. Michael Gibson, MD is a leading interventional cardiologist, cardiovascular researcher, and educator at Harvard Medical School , where he serves as the Chief Executive Officer of the Baim Institute and PERFUSE Research Institute . These institutes have led over 1,000 studies and 5,500 peer-reviewed publications, including 144 in the New England Journal of Medicine . Key Roles: Director of Coronary Care Unit, Cardiac Catheterization Laboratory Director, Chief of Cardiology, Vice Chairman of Medicine Education: BS, MS, and MD from the University of Chicago (Phi Beta Kappa, AOA), followed by training at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center Research Focus: Pioneered the open artery and microvasculature hypothesis in heart attacks, developed widely used coronary blood flow measures (TIMI frame count, TIMI myocardial perfusion grade), and leads virtual clinical trials like the HEARTLINE trial of the Apple Watch. Current work includes Factor XI inhibitors (milvexian) and apolipoprotein AI infusions for cardiovascular disease. Scientific Contributions: Over 148,000 citations, 659 publications, and leadership in guidelines like the Bleeding Academic Research Consortium . Notable trials include ANDexanet Alfa for anticoagulant reversal and the PEERLESS study comparing mechanical thrombectomy to thrombolysis in pulmonary embolism. Leadership: FDA Cardiorenal Panel member (2017–2021), founder of WikiDoc.org and ClinicalTrialsResults.org Media Influence: Chief Medical Correspondent for the American College of Cardiology, 435K+ social media followers Scientific Awards: Consistently ranked among the world’s most highly cited authors (Thomson Reuters, 2014–present), 50 Most Influential Voices in Healthcare (Medika Life, 2021), and Boston’s Top Doctors (multiple years).

پروفایل رسمی دانشگاه

Sara E. Wobkerمشاهده پروفایل

دانشیار

University of North Carolina at Chapel HillUnited States

Sara E. Wobker, MD, MPH, is an Associate Professor in both the Department of Pathology and Laboratory Medicine and the Department of Urology at the University of North Carolina at Chapel Hill . She also serves as Director of Anatomic Pathology , Director of Genitourinary Pathology , and Director of Surgical Pathology . Her research focuses on genitourinary malignancies , particularly the molecular characterization of rare variants of bladder carcinoma . She aims to translate histologic findings into molecular discoveries to improve patient care, with a recent emphasis on tumor microenvironment dynamics and immunotherapy response mechanisms in muscle-invasive bladder cancer. Analysis of her 15 most recent articles (2024-2021) reveals a strong trend in immunotherapy response , molecular subtyping , and diagnostic standardization for genitourinary cancers. Key subfields include FGFR inhibition , TFE3 gene fusions , clinicogenomic features , and pathology protocol optimization . Scientific Awards UNC Junior Faculty Development Award (2018-2019) As Faculty Director of the Pathology Services Core, she supports clinical trials , translational studies , and basic science research . She collaborates extensively with interdisciplinary teams in the UNC Lineberger Comprehensive Cancer Center, contributing to updates in renal and prostate cancer grading through the Genitourinary Pathology Society (GUPS).

پروفایل رسمی دانشگاه

Jaume Moraمشاهده پروفایل

استاد بالینی

German Cancer Research CenterGermany

Jaume Mora is a Clinical Professor in the Department of Pediatrics at the University of Barcelona, specializing in Pediatric and Molecular Oncology. He earned a PhD in Molecular Oncology (2003) following residency training in general pediatrics (1992-1995) and a pediatric Hematology/Oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC), New York (1996-1998). He later completed a Research Fellowship in molecular pathology at MSKCC (1999-2001) before returning to Barcelona in 2002 as a leader in pediatric oncology. PhD in Molecular Oncology (2003) Residency: General Pediatrics (1992-1995) Fellowship: Pediatric Hematology/Oncology at MSKCC (1996-1998) Research Fellowship: Molecular Pathology at MSKCC (1999-2001) His research focuses on pediatric cancers like neuroblastoma and Ewing sarcoma, with emphasis on molecular pathology, targeted therapies, and cancer immunotherapy. Recent work explores HDAC6 inhibition in Ewing sarcoma, AKT inhibitors for vascular malformations, and extracellular vesicle-mediated tumor-stromal interactions. Key contributions include clinical trials on naxitamab for high-risk neuroblastoma, highlighting its efficacy and safety. His publications span journals like Annals of Oncology , Oncogene , and Translational Research , reflecting interdisciplinary collaboration.

پروفایل رسمی دانشگاه